重症凝血反应评估监测体系与平台——基于表型与时程动态画像谱的精准化管理

Comprehensive Assessment and Monitoring Platform for Critical Coagulation Response:Precision Management Based on Phenotype and Time-Course Profiling

  • 摘要: 在重症医学领域,凝血功能紊乱已不再被视为孤立的止血异常或血栓事件,而是宿主对严重损伤产生的宿主/机体失调反应(host/organ unregulated response, HOUR)的核心效应器。传统以血浆凝固试验为主的监测模式具有明显滞后性,难以捕捉重症早期“高凝状态”以及内皮损伤的动态演变。本文系统构建了“重症凝血反应评估监测体系”,确立了“高凝是常态,低凝是后果”的认知框架,提出以全血黏弹性检测(viscoelastic testing, VET)为核心,深度融合血栓四项分子标志物,并整合传统凝血指标与血小板功能分析,形成多维度的凝血反应表型评估方案。同时,详细阐述了通过动态监测描绘凝血紊乱的时程画像,早期识别内皮糖萼脱落、凝血酶爆发以及纤溶关闭等关键病理环节,进而区分“生理性”凝血反应与“病理性”凝血疾病乃至弥散性血管内凝血。在此基础上,提出基于表型导向的精准抗凝、成分输血及内皮保护策略,旨在为临床提供从机制解析到床旁决策的完整闭环管理方案。进一步将凝血反应管理定位为HOUR管理的关键节点,这不仅关乎血栓与出血的防控,更是预防病情重症化、降低多器官功能衰竭发生率、改善重症患者预后的重要干预路径。

     

    Abstract: In the field of critical care medicine, coagulopathy is no longer viewed as an isolated hemostatic abnormality or thrombotic event, but rather as a core effector of the host/organ unregulated response (HOUR) to severe injury. Conventional monitoring modalities based primarily on plasma coagulation tests exhibit considerable lag and fail to capture the dynamic evolution of hypercoagulability and endothelial injury in the early phase of critical illness. This article systematically proposes the "Critical Care Coagulation Response Assessment and Monitoring System" and establishes a novel conceptual framework that "hypercoagulability is the norm, while hypocoagulability is the consequence." We advocate for viscoelastic testing (VET) as the cornerstone, deeply integrated with the four thrombus-related molecular biomarkers, and combined with conventional coagulation parameters and platelet function analysis, to constitute a multidimensional phenotypic assessment protocol for coagulation responses. Furthermore, we elaborate on how dynamic monitoring of coagulation responses enables the construction of a temporal profile of coagulopathic evolution, allowing early identification of key pathological processes including endothelial glycocalyx shedding, thrombin burst, and fibrinolysis shutdown, thereby distinguishing physiological coagulation responses from pathological coagulopathy/disease and even disseminated intravascular coagulation (DIC). On this basis, we propose phenotype-guided precision anticoagulation, component blood product transfusion, and endothelial protective strategies, aiming to provide clinicians with a complete closed-loop management framework from mechanistic elucidation to bedside decision-making. Importantly, we position coagulation response management as a critical node in HOUR stewardship-not only pivotal for thrombotic and hemorrhagic risk control, but also a key intervention pathway to prevent disease progression, reduce the incidence of multiple organ dysfunction syndrome (MODS), and ultimately improve outcomes in critically ill patients.

     

/

返回文章
返回